Postmenopausal Bleeding: Differential Diagnosis and Comprehensive Evaluation

Introduction

Menopause, clinically defined as 12 consecutive months without menstruation due to the depletion of ovarian follicles, marks a significant transition in a woman’s life. In the United States, the average age of menopause is 51. Any vaginal bleeding occurring after menopause, termed postmenopausal bleeding (PMB), is considered abnormal and necessitates prompt medical attention. Alarmingly, PMB accounts for approximately two-thirds of gynecologic consultations among postmenopausal women. While the most frequent cause of PMB is attributed to atrophy of the lower reproductive tract, it is crucial to recognize that vaginal bleeding is the primary presenting symptom in 90% of postmenopausal women diagnosed with endometrial cancer.

Given that early diagnosis and appropriate management are critical for a favorable prognosis, especially in cases of malignancy, any instance of postmenopausal bleeding warrants thorough and timely evaluation. This evaluation should encompass a comprehensive clinical examination alongside diagnostic studies, notably endometrial biopsy and imaging techniques. Management strategies are then tailored based on the identified underlying cause. This resource is designed for healthcare professionals to enhance their proficiency in selecting the most suitable diagnostic approaches, effectively managing the diverse etiologies of postmenopausal bleeding, and promoting seamless interprofessional collaboration to optimize patient outcomes in cases of PMB.

Etiology of Postmenopausal Bleeding

While patients often mistakenly attribute postmenopausal bleeding to uterine causes, believing it to be a recurrence of menstruation, it is important to consider that the source of bleeding can originate from various sites, including the urethra, vulva, vagina, cervix, or rectum. Genitourinary atrophy stands out as the most prevalent cause of postmenopausal bleeding, accounting for approximately 60% of cases. It’s also critical to acknowledge that some instances of PMB may stem from non-gynecologic origins, such as the urethra, bladder, or gastrointestinal tract, and can be misidentified as vaginal bleeding.

A range of underlying conditions can lead to postmenopausal bleeding, including:

• Vaginal atrophy
• Endometrial atrophy
• Urogenital infections (e.g., vaginitis, cervicitis, cystitis, endometrial tuberculosis)
• Medications (e.g., estrogen, tamoxifen, anticoagulants)
• Uterine leiomyomas (fibroids)
• Genital tract malignancies (e.g., endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer)
• Vaginal foreign bodies
• Endometrial polyps
• Endometrial hyperplasia with or without atypia

Understanding this broad spectrum of potential etiologies is crucial for healthcare providers to accurately diagnose and manage postmenopausal bleeding.

Epidemiology of Postmenopausal Bleeding

Vaginal bleeding is a relatively common concern among postmenopausal women, with reports indicating that up to 10% of this population experience it. Significantly, postmenopausal bleeding is the presenting complaint in approximately two-thirds of gynecologic office visits for women in this age group. Interestingly, the incidence of PMB appears to decrease as women age further into postmenopause. In the initial years following menopause onset, bleeding is reported in about 40% of women annually. However, this rate significantly drops to around 4% per year beyond three years post-menopause.

Endometrial cancer is a particularly concerning etiology of PMB. It ranks as the fifth leading cause of cancer-related deaths among women in the United States and is the fourth most frequently diagnosed cancer in women overall. Notably, endometrial cancer is the most common gynecologic malignancy in women, and it is the predominant type of uterine cancer, accounting for 92% of all uterine cancer cases. A striking statistic is that over 90% of postmenopausal women with endometrial cancer initially present with postmenopausal bleeding. While endometrial cancer is less common in women younger than 50, the global incidence is on the rise. This increase is largely attributed to the growing prevalence of established risk factors for endometrial cancer, such as obesity and delayed menopause. Projections suggest that the number of new endometrial cancer diagnoses is anticipated to double by the year 2030, highlighting the importance of awareness and early detection of postmenopausal bleeding.

Pathophysiology of Postmenopausal Bleeding

Atrophic endometrium is the most frequently identified cause of postmenopausal bleeding. The reduced estrogen levels characteristic of the postmenopausal state lead to genitourinary atrophy. Within the uterus, the endometrial lining becomes thin and atrophic, lacking sufficient fluid to lubricate the cavity. This dryness can result in epithelial micro-erosions and subsequent chronic inflammation. Chronic endometritis, stemming from atrophy, can manifest as vaginal spotting or light bleeding. Pelvic ultrasounds in these cases typically reveal a thin endometrial stripe and an otherwise normal appearance of the uterus and ovaries, which are often smaller in size.

Conversely, prolonged exposure to estrogen without progesterone opposition can foster the development of premalignant or malignant endometrial conditions. Sources of such unopposed estrogen include systemic estrogen-only hormone therapy, obesity (due to estrogen conversion in adipose tissue), and estrogen-secreting tumors. Furthermore, certain genetic predispositions, such as Lynch syndrome and Cowden disease, are associated with an increased risk of endometrial cancer. Emerging research also indicates that carriers of BRCA gene mutations, particularly BRCA1 mutations, may have a slightly elevated risk of developing endometrial cancer.

Histopathology of Postmenopausal Endometrial Bleeding

Postmenopausal Endometrial Histologic Findings

The hypoestrogenic environment of postmenopause induces distinct changes in the endometrium, readily observable under microscopic examination. In contrast to the premenopausal proliferative endometrium, which is characterized by regularly arranged glands lined by simple epithelial cells within the stroma in a 1:1 gland-to-stroma ratio and mitotic activity, the postmenopausal endometrium presents a different histologic picture. Normal postmenopausal endometrial tissue shows widely spaced glands that vary in size from small to cystically dilated. Crucially, the mitotic proliferative activity that is a hallmark of premenopausal endometrium is typically absent in postmenopausal endometrial cells.

Pathologic endometrial findings in postmenopausal bleeding exhibit diverse histologic features depending on the underlying cause. For example, endometrial polyps often display cellular immaturity and cystic hyperplasia in their histopathology. Uterine fibroids, on the other hand, are characterized by the presence of smooth muscle fibers. Both endometrial polyps and uterine fibroids carry an increased risk of malignant transformation in postmenopausal women. Among the most concerning abnormal histologic findings in women experiencing PMB are endometrial hyperplasia and carcinoma.

Endometrial Hyperplasia Histologic Findings

Endometrial hyperplasia, a precursor to endometrial cancer, is histologically characterized by several features including:

• Increased crowding of endometrial glands
• Disordered proliferation of glands
• An elevated gland-to-stroma ratio

While the precise gland-to-stroma ratio that defines endometrial hyperplasia is debated, a ratio of 2:1 is commonly used by pathologists. In benign endometrial hyperplasia, the gland cytology remains normal, with only occasional mitotic figures observed. However, endometrial intraepithelial neoplasia (EIN), considered a premalignant condition, typically displays gland crowding and abnormal gland nuclei upon histological examination.

Endometrial Cancer Histologic Findings

Endometrial cancer is a significant concern in postmenopausal bleeding, and it is histologically subclassified into type I and type II based on morphology, grade, and hormone receptor status.

• Endometrial Carcinoma Type 1: This is the more common type, typically low-grade, well-differentiated, endometrioid adenocarcinoma, and is often estrogen-sensitive. Type 1 endometrial cancer is generally associated with a better prognosis.

• Endometrial Carcinoma Type 2: These are less frequent, high-grade, poorly differentiated, and more aggressive forms of uterine cancer. Type 2 includes clear cell carcinoma, sarcoma, carcinosarcoma, and papillary serous histologies. Type 2 endometrial cancers are characterized by a higher risk of extrauterine disease at diagnosis and a less favorable prognosis compared to type I tumors. For instance, papillary serous carcinoma, though accounting for only 10% of uterine cancers, is responsible for approximately 40% of endometrial cancer-related deaths.

History and Physical Examination in Postmenopausal Bleeding

A detailed medical history is paramount when evaluating postmenopausal bleeding. It is essential for identifying potential underlying causes and confirming the patient’s menopausal status. Ruling out malignancy, particularly endometrial cancer, is the most critical objective in the evaluation of PMB. Clinicians should obtain a comprehensive history encompassing the following key elements:

History of Present Illness

To effectively evaluate the differential diagnoses of postmenopausal bleeding and clinically verify the patient’s menopausal state, clinicians should gather information regarding:

• The nature of the current bleeding episode
• Any associated symptoms

Heavy menstrual bleeding or irregular uterine bleeding patterns may suggest structural abnormalities such as leiomyomas or polyps, hyperplasia, or malignancy. Key characteristics of the bleeding to ascertain include:

• Onset
• Duration
• Heaviness
• Precipitating factors (e.g., bleeding after intercourse or wiping)

Associated symptoms that warrant investigation include:

• Fever
• Pelvic pain
• Dysuria
• Vasomotor symptoms (e.g., hot flashes)
• Dyspareunia
• Vaginal dryness

Physical Examination

The physical examination in patients with postmenopausal bleeding should include a thorough assessment of both the external and internal anatomy of the genital tract. A speculum examination is essential for:

• Visualizing the bleeding site
• Identifying genital lesions
• Detecting lacerations
• Assessing for urethral prolapse
• Evaluating for signs of genitourinary atrophy

Signs of genitourinary atrophy typically include pale, dry vaginal epithelium with a loss of rugae. Erythema, petechiae, friability, and discharge may indicate inflammation or infection. A bimanual examination should also be performed to palpate for:

• Pelvic masses
• Abdominal distention
• Enlarged lymph nodes

Evaluation of Postmenopausal Bleeding

Diagnostic Studies

In addition to clinical assessment, the diagnostic evaluation of postmenopausal bleeding is primarily focused on excluding endometrial hyperplasia or malignancy. The American College of Obstetricians and Gynecologists (ACOG) recommends either transvaginal ultrasound or endometrial biopsy as initial steps in evaluating women with PMB who are at low risk. Performing both tests simultaneously is generally not necessary. However, endometrial biopsy is recommended as the first-line diagnostic test for individuals with risk factors for endometrial cancer or in cases of recurrent postmenopausal bleeding. Laboratory studies may be considered to assess for complications arising from heavy vaginal bleeding and to help rule out certain differential diagnoses.

Endometrial Biopsy

Endometrial sampling is a crucial first-line test in the evaluation of any patient with postmenopausal bleeding. This procedure provides tissue for histologic diagnosis, which is essential for detecting malignancies. Further indications for endometrial sampling in patients with PMB include:

• Persistent or recurrent PMB, even when transvaginal ultrasound shows a thin endometrial stripe.
• Presence of risk factors for endometrial cancer (e.g., obesity, smoking, exposure to unopposed estrogen).
• Endometrial lining thickness greater than 4 mm on transvaginal ultrasound in a woman with PMB.
• Inadequate visualization of the endometrium during imaging studies.

ACOG also recommends endometrial sampling for women older than 45 years with abnormal uterine bleeding. Common methods for endometrial sampling include dilation and curettage (D&C) and outpatient procedures using disposable thin plastic devices inserted into the endometrial cavity through the endocervical opening, typically without anesthesia. D&C, often with hysteroscopy, has been used for many years for histologic assessment and has a diagnostic sensitivity exceeding 90% for endometrial cancer. Office endometrial biopsy using flexible plastic samplers has demonstrated similar diagnostic accuracy. However, endometrial biopsy can sometimes yield insufficient tissue for diagnosis, with sampling failure rates reported up to 54%. The diagnostic accuracy of endometrial sampling is directly related to the amount of tissue collected. If initial endometrial sampling is inadequate, a follow-up ultrasound may be performed. If this ultrasound reveals a thin endometrial stripe and vaginal bleeding does not persist, further evaluation may not be necessary.

Imaging Studies

Transvaginal ultrasound is frequently used as a first-line imaging modality to assess postmenopausal bleeding, particularly in patients without immediate indications for histologic assessment. ACOG guidelines recommend measuring endometrial thickness on a long-axis uterine view, anterior to posterior, at the thickest portion of the endometrial stripe. An endometrial stripe thickness of 4 mm or less has a high negative predictive value (>99%) for endometrial carcinoma, indicating a very low likelihood of cancer when the stripe is thin. However, even with a thin stripe, the possibility of endometrial cancer is not entirely eliminated. Conversely, an endometrial stripe thickness greater than 4 mm warrants further investigation, typically with endometrial biopsy. Ultrasound imaging can also identify other pelvic pathologies, such as leiomyomas or adnexal masses. If the endometrial stripe is not adequately visualized on ultrasound, further evaluation with endometrial sampling is indicated. Because endometrial imaging is not definitively diagnostic and endometrial thickness alone cannot rule out malignancy, endometrial biopsy is still recommended for persistent or recurrent PMB, even in patients with a thin endometrial lining.

A thickened endometrial stripe can be caused by various conditions including hyperplasia, malignancy, and intracavitary lesions like leiomyomas and endometrial polyps. In cases where ultrasound findings suggest intracavitary lesions or when there is a clinical suspicion based on history (e.g., previous polyps), additional imaging techniques may be beneficial. These include saline-infused sonohysterography or hysterosalpingography. Pelvic computed tomography (CT) and magnetic resonance imaging (MRI) are sometimes used to further characterize urogenital pathology initially detected on ultrasound. However, hysteroscopy with dilation and curettage remains the gold standard for both diagnostic sampling and therapeutic excision of certain PMB etiologies, such as endometrial polyps. Hysteroscopy allows for direct visualization of the uterine cavity and targeted biopsies. Blind endometrial sampling without hysteroscopy may miss focal lesions or intrauterine pathology, and mass lesions can sometimes deflect flexible disposable sampling devices. Therefore, for patients with insufficient endometrial sampling or persistent vaginal bleeding in whom focal lesions may have been missed, further imaging evaluation, hysteroscopy with D&C, or directed biopsy should be considered.

Laboratory Studies

In evaluating postmenopausal bleeding, certain laboratory tests may be considered to help exclude differential diagnoses and assess for secondary complications. These may include:

• Complete Blood Count (CBC): To evaluate for anemia secondary to blood loss.
• Thyroid-Stimulating Hormone (TSH): To assess thyroid function, as thyroid disorders can sometimes contribute to abnormal bleeding.
• Coagulation Studies (e.g., prothrombin time, partial thromboplastin time): To evaluate for bleeding disorders.
• Vaginal Cultures: To test for sexually transmitted infections and other genital infections, if clinically indicated.
• Pregnancy Test: In women who have experienced early menopause (i.e., before age 40), a pregnancy test is typically performed to rule out pregnancy-related bleeding.
• Papanicolaou (Pap) Smear: While not diagnostic for PMB, a Pap smear can suggest etiologies such as cervicitis, sexually transmitted diseases, and cervical or endometrial cancers.

Treatment and Management of Postmenopausal Bleeding

The management of postmenopausal bleeding is primarily guided by the underlying cause. However, other factors such as patient comorbidities, preferences, and the characteristics of the PMB (e.g., heaviness, duration) are also taken into account when determining the most appropriate treatment approach.

Genitourinary Atrophy: Bleeding due to genitourinary atrophy is often self-limiting and may not require specific treatment. For associated vaginal dryness, non-hormonal vaginal moisturizers and lubricants can be effective, particularly for maintaining sexual activity. Topical estrogen therapy is the preferred pharmacologic treatment for vulvovaginal atrophy symptoms and can effectively reverse these changes. Oral hormone replacement therapy or hormonal receptor modulators like ospemifene may be considered if topical treatments are insufficient.

Endometrial Polyps: Endometrial polyps are responsible for approximately 30% of PMB cases. While many polyps are asymptomatic, they can cause bleeding. About 1% of endometrial polyps are malignant, with malignancy risk being higher in postmenopausal women. Therefore, symptomatic endometrial polyps in postmenopausal women should be removed and examined histologically. Surgical excision should also be considered for asymptomatic women at higher risk of malignancy (e.g., those with large polyps, tamoxifen use, obesity, or diabetes). Hysteroscopic polypectomy is the preferred treatment method as it allows for both directed biopsies and polyp excision in a single procedure.

Uterine Leiomyoma (Fibroids): Leiomyomas are typically benign and often regress after menopause, often requiring no treatment if asymptomatic. However, a small percentage can be malignant, particularly in postmenopausal women. Benign leiomyomas can occasionally grow or become symptomatic in postmenopausal patients, especially in obese women due to peripheral estrogen conversion. In women with PMB and uterine fibroids, in the absence of other identifiable causes, pharmacologic therapy (e.g., aromatase inhibitors, selective estrogen receptor modulators) or surgical options (myomectomy, hysterectomy) may be considered. Because leiomyosarcomas cannot be definitively ruled out through imaging or laboratory tests, thorough patient counseling and shared decision-making are crucial in managing symptomatic postmenopausal women with fibroids.

Genitourinary Infection: Treatment for sexually transmitted infections and other genital infections is guided by vaginal culture results. Oral doxycycline may be considered for endometritis.

Cervical, Vaginal, and Vulvar Carcinomas: Treatment modalities for these malignancies typically include surgery and chemoradiotherapy, depending on the stage of the cancer.

Endometrial Hyperplasia or Malignancy: Management of endometrial hyperplasia ranges from medical to surgical approaches, individualized based on clinical factors and comorbidities. Endometrial carcinoma requires surgical treatment and staging, typically by a gynecologic oncologist. Chemotherapy and radiation therapy may also be indicated in certain cases.

Hematuria: Genitourinary atrophy can sometimes lead to asymptomatic microscopic hematuria. Evaluation for urinary malignancy in asymptomatic, low-risk women (non-smokers, no gross hematuria) is generally recommended by ACOG only if urine microscopy shows more than 25 red blood cells per high-power field. Symptomatic acute cystitis should be treated with appropriate antibiotics.

Medications: Postmenopausal hormone replacement therapy can commonly cause PMB in the initial 2-3 months after starting, which usually resolves spontaneously. However, persistent or recurrent PMB beyond the first few months of therapy requires evaluation for endometrial pathology. For PMB associated with anticoagulant medications, progestin therapy may help manage bleeding until anticoagulants can be discontinued. Long-term strategies may be needed for patients requiring lifelong anticoagulation.

Differential Diagnosis of Postmenopausal Bleeding

When evaluating patients with postmenopausal bleeding, it is crucial to consider a broad differential diagnosis. PMB can arise from both gynecologic and non-gynecologic sources. Conditions to consider in the differential diagnosis include:

• Urogenital infections (e.g., endometritis, vaginitis, cervicitis, cystitis)
• Uterine leiomyomas
• Genital tract malignancies (endometrial, cervical, vaginal, vulvar cancers)
• Vaginal foreign bodies
• Gastrointestinal conditions (e.g., diverticulitis, colitis, hemorrhoids, malignancy)
• Genitourinary atrophy
• Radiation effects on adjacent organs (e.g., hemorrhagic cystitis, proctitis, necrosis)

A thorough history, physical examination, and appropriate diagnostic testing are essential to differentiate between these potential causes of postmenopausal bleeding.

Prognosis of Postmenopausal Bleeding

The prognosis for postmenopausal bleeding is generally favorable. The most common causes of PMB are benign and treatable. Furthermore, the prognosis for endometrial cancer, the most common malignancy presenting as PMB, is significantly better than many other cancers. Endometrial cancer has a 5-year survival rate of approximately 90% when detected and treated early. However, it is important to note that in patients diagnosed with endometrial hyperplasia who subsequently undergo hysterectomy, a significant proportion (around 43%) are found to have undiagnosed concurrent endometrial carcinoma. This underscores the importance of thorough evaluation and appropriate management of endometrial hyperplasia.

Complications of Postmenopausal Bleeding

The primary complication directly related to postmenopausal bleeding is secondary anemia, which occurs in approximately 10% of postmenopausal women experiencing PMB. Other potential complications are typically associated with the underlying cause of the bleeding. For example, genitourinary atrophy can negatively impact quality of life due to reduced sexual intimacy and self-esteem. Uterine fibroids can cause pelvic discomfort and other symptoms. Furthermore, treatments for the etiologies of PMB can also have their own complications. For instance, pharmacologic therapy for endometrial hyperplasia with megestrol may lead to side effects like weight gain, nausea, venous thromboembolism, and persistent vaginal bleeding.

Consultations for Postmenopausal Bleeding

Gynecologists are frequently consulted for the evaluation and management of patients with postmenopausal bleeding. If a urologic etiology is suspected, consultation with a urologist or urogynecologist may be beneficial. For patients diagnosed with a gynecologic malignancy, consultation with a gynecologic oncologist is crucial, as outcomes are generally improved when care is managed by gynecologic oncology specialists.

Deterrence and Patient Education Regarding Postmenopausal Bleeding

Clinicians play a vital role in educating perimenopausal patients about the menopausal transition and the typical changes they may experience in their menstrual cycles. It is essential to educate patients that any bleeding after menopause is established is considered abnormal and requires medical evaluation. Patients should be instructed on when to seek medical attention for abnormal vaginal bleeding and should be asked about such bleeding during routine office visits. Primary care clinicians, who are often the first point of contact for women experiencing PMB, should educate patients on modifiable risk factors for endometrial hyperplasia and cancer, such as obesity and unopposed estrogen exposure. Furthermore, clinicians should inform patients about preventive strategies, such as intrauterine devices, which have been shown to reduce the risk of uterine cancer by up to 50%.

Enhancing Healthcare Team Outcomes in Postmenopausal Bleeding Management

Managing postmenopausal bleeding effectively presents a diagnostic challenge due to its diverse range of potential causes. Optimal patient care requires a comprehensive and collaborative approach involving an interprofessional healthcare team. This team ideally includes physicians, advanced practice providers, nurses, pharmacists, radiologists, and pathologists, each contributing their expertise to the evaluation and management process. Radiology and pathology specialists work closely with primary care clinicians, gynecologists, and other team members to ensure accurate diagnosis of the underlying cause and development of a tailored treatment plan.

Effective interprofessional communication and shared decision-making are paramount for aligning team efforts, improving patient outcomes, and enhancing patient satisfaction. By fostering a holistic and integrated care approach, the team ensures not only the accurate identification and treatment of the condition but also the provision of comprehensive support and safety throughout the patient’s healthcare journey. For premalignant gynecologic conditions, timely consultation with gynecologic oncologists is critical for optimizing care and improving clinical outcomes. This level of coordination underscores the importance of mutual respect, clear communication, and shared responsibilities among all healthcare professionals involved to deliver exceptional care that prioritizes patient safety, enhances outcomes, and strengthens overall team performance.

Review Questions

(The review questions section from the original article can be included here if desired, though it is omitted based on the instructions to only include title and content.)

References

1.Carugno J. Clinical management of vaginal bleeding in postmenopausal women. Climacteric. 2020 Aug;23(4):343-349. [PubMed: 32233689]

2.Clarke MA, Long BJ, Del Mar Morillo A, Arbyn M, Bakkum-Gamez JN, Wentzensen N. Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018 Sep 01;178(9):1210-1222. [PMC free article: PMC6142981] [PubMed: 30083701]

3.Santoro N, Roeca C, Peters BA, Neal-Perry G. The Menopause Transition: Signs, Symptoms, and Management Options. J Clin Endocrinol Metab. 2021 Jan 01;106(1):1-15. [PubMed: 33095879]

4.Ring KL, Mills AM, Modesitt SC. Endometrial Hyperplasia. Obstet Gynecol. 2022 Dec 01;140(6):1061-1075. [PubMed: 36357974]

5.ACOG Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding. Obstet Gynecol. 2018 May;131(5):e124-e129. [PubMed: 29683909]

6.Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and Management of Endometrial Cancer. Am Fam Physician. 2016 Mar 15;93(6):468-74. [PubMed: 26977831]

7.Smith PP, O’Connor S, Gupta J, Clark TJ. Recurrent postmenopausal bleeding: a prospective cohort study. J Minim Invasive Gynecol. 2014 Sep-Oct;21(5):799-803. [PubMed: 24681065]

8.Swain M, Kulkarni AD. Endometrium at Menopause: The Pathologist’s View. J Midlife Health. 2021 Oct-Dec;12(4):310-315. [PMC free article: PMC8849152] [PubMed: 35264839]

9.Jo HC, Baek JC, Park JE, Park JK, Cho IA, Choi WJ, Sung JH. Clinicopathologic Characteristics and Causes of Postmenopausal Bleeding in Older Patients. Ann Geriatr Med Res. 2018 Dec;22(4):189-193. [PMC free article: PMC7387628] [PubMed: 32743272]

10.Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K, Veneris JL. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019 Jul;69(4):258-279. [PubMed: 31074865]

11.Practice Bulletin No. 149: Endometrial cancer. Obstet Gynecol. 2015 Apr;125(4):1006-1026. [PubMed: 25798986]

12.Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022 Apr 09;399(10333):1412-1428. [PubMed: 35397864]

13.Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, Oaknin A. Endometrial cancer. Nat Rev Dis Primers. 2021 Dec 09;7(1):88. [PMC free article: PMC9421940] [PubMed: 34887451]

14.Ferenczy A. Pathophysiology of endometrial bleeding. Maturitas. 2003 May 30;45(1):1-14. [PubMed: 12753939]

15.Matanes E, Volodarsky-Perel A, Eisenberg N, Rottenstreich M, Yasmeen A, Mitric C, Lau S, Salvador S, Gotlieb WH, Kogan L. Endometrial Cancer in Germline BRCA Mutation Carriers: A Systematic Review and Meta-analysis. J Minim Invasive Gynecol. 2021 May;28(5):947-956. [PubMed: 33249269]

16.Nijkang NP, Anderson L, Markham R, Manconi F. Endometrial polyps: Pathogenesis, sequelae and treatment. SAGE Open Med. 2019;7:2050312119848247. [PMC free article: PMC6501471] [PubMed: 31105939]

17.Wen KC, Horng HC, Wang PH, Chen YJ, Yen MS, Ng HT., Taiwan Association of Gynecology Systematic Review Group. Uterine sarcoma Part I-Uterine leiomyosarcoma: The Topic Advisory Group systematic review. Taiwan J Obstet Gynecol. 2016 Aug;55(4):463-71. [PubMed: 27590365]

18.Parkash V, Fadare O, Tornos C, McCluggage WG. Committee Opinion No. 631: Endometrial Intraepithelial Neoplasia. Obstet Gynecol. 2015 Oct;126(4):897. [PubMed: 26393443]

19.Klein DA, Paradise SL, Reeder RM. Amenorrhea: A Systematic Approach to Diagnosis and Management. Am Fam Physician. 2019 Jul 01;100(1):39-48. [PubMed: 31259490]

20.Nappi RE, Martini E, Cucinella L, Martella S, Tiranini L, Inzoli A, Brambilla E, Bosoni D, Cassani C, Gardella B. Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women. Front Endocrinol (Lausanne). 2019;10:561. [PMC free article: PMC6712495] [PubMed: 31496993]

21.Gibson CJ, Huang AJ, McCaw B, Subak LL, Thom DH, Van Den Eeden SK. Associations of Intimate Partner Violence, Sexual Assault, and Posttraumatic Stress Disorder With Menopause Symptoms Among Midlife and Older Women. JAMA Intern Med. 2019 Jan 01;179(1):80-87. [PMC free article: PMC6583410] [PubMed: 30453319]

22.Committee on Practice Bulletins—Gynecology. Practice bulletin no. 128: diagnosis of abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol. 2012 Jul;120(1):197-206. [PubMed: 22914421]

23.Jubber I, Ong S, Bukavina L, Black PC, Compérat E, Kamat AM, Kiemeney L, Lawrentschuk N, Lerner SP, Meeks JJ, Moch H, Necchi A, Panebianco V, Sridhar SS, Znaor A, Catto JWF, Cumberbatch MG. Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors. Eur Urol. 2023 Aug;84(2):176-190. [PubMed: 37198015]

24.van Hunsel FP, Kampschöer P. [Postmenopausal bleeding and dietary supplements: a possible causal relationship with hop- and soy-containing preparations]. Ned Tijdschr Geneeskd. 2012;156(41):A5095. [PubMed: 23062258]

25.Chandrareddy A, Muneyyirci-Delale O, McFarlane SI, Murad OM. Adverse effects of phytoestrogens on reproductive health: a report of three cases. Complement Ther Clin Pract. 2008 May;14(2):132-5. [PubMed: 18396257]

26.Unfer V, Casini ML, Costabile L, Mignosa M, Gerli S, Di Renzo GC. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2004 Jul;82(1):145-8, quiz 265. [PubMed: 15237003]

27.Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012 Aug;120(2 Pt 1):383-97. [PubMed: 22825101]

28.Terzic MM, Aimagambetova G, Terzic S, Norton M, Bapayeva G, Garzon S. Current role of Pipelle endometrial sampling in early diagnosis of endometrial cancer. Transl Cancer Res. 2020 Dec;9(12):7716-7724. [PMC free article: PMC8798375] [PubMed: 35117374]

29.Kaan M. [Arguments and counter-arguments about the orthodontic treatment of missing incisors. Literature review]. Fogorv Sz. 2010 Sep;103(3):83-8. [PubMed: 21058493]

30.Sany O, Singh K, Jha S. Correlation between preoperative endometrial sampling and final endometrial cancer histology. Eur J Gynaecol Oncol. 2012;33(2):142-4. [PubMed: 22611951]

31.Ferenczy A, Shore M, Guralnick M, Gelfand MM. The Kevorkian curette. An appraisal of its effectiveness in endometrial evaluation. Obstet Gynecol. 1979 Aug;54(2):262-7. [PubMed: 460766]

32.Dijkhuizen FP, Mol BW, Brölmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000 Oct 15;89(8):1765-72. [PubMed: 11042572]

33.Stovall TG, Ling FW, Morgan PL. A prospective, randomized comparison of the Pipelle endometrial sampling device with the Novak curette. Am J Obstet Gynecol. 1991 Nov;165(5 Pt 1):1287-90. [PubMed: 1957847]

34.Reijnen C, Visser NCM, Bulten J, Massuger LFAG, van der Putten LJM, Pijnenborg JMA. Diagnostic accuracy of endometrial biopsy in relation to the amount of tissue. J Clin Pathol. 2017 Nov;70(11):941-946. [PubMed: 28389441]

35.Manchanda R, Thapa S. An overview of the main intrauterine pathologies in the postmenopausal period. Climacteric. 2020 Aug;23(4):384-387. [PubMed: 32520598]

36.Wouk N, Helton M. Abnormal Uterine Bleeding in Premenopausal Women. Am Fam Physician. 2019 Apr 01;99(7):435-443. [PubMed: 30932448]

37.Sasaki LMP, Andrade KRC, Figueiredo ACMG, Wanderley MDS, Pereira MG. Factors Associated with Malignancy in Hysteroscopically Resected Endometrial Polyps: A Systematic Review and Meta-Analysis. J Minim Invasive Gynecol. 2018 Jul-Aug;25(5):777-785. [PubMed: 29454147]

38.Ulin M, Ali M, Chaudhry ZT, Al-Hendy A, Yang Q. Uterine fibroids in menopause and perimenopause. Menopause. 2020 Feb;27(2):238-242. [PMC free article: PMC6994343] [PubMed: 31834160]

39.Hosh M, Antar S, Nazzal A, Warda M, Gibreel A, Refky B. Uterine Sarcoma: Analysis of 13,089 Cases Based on Surveillance, Epidemiology, and End Results Database. Int J Gynecol Cancer. 2016 Jul;26(6):1098-104. [PubMed: 27177280]

40.Di Caprio R, Lembo S, Di Costanzo L, Balato A, Monfrecola G. Anti-inflammatory properties of low and high doxycycline doses: an in vitro study. Mediators Inflamm. 2015;2015:329418. [PMC free article: PMC4421036] [PubMed: 25977597]

41.Jhingran A. Updates in the treatment of vaginal cancer. Int J Gynecol Cancer. 2022 Mar;32(3):344-351. [PMC free article: PMC8921584] [PubMed: 35256422]

42.Small W, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN, Gaffney DK. Cervical cancer: A global health crisis. Cancer. 2017 Jul 01;123(13):2404-2412. [PubMed: 28464289]

43.Committee Opinion No.703: Asymptomatic Microscopic Hematuria in Women. Obstet Gynecol. 2017 Jun;129(6):e168-e172. [PubMed: 28368896]

44.Dichman ML, Rosenstock SJ, Shabanzadeh DM. Antibiotics for uncomplicated diverticulitis. Cochrane Database Syst Rev. 2022 Jun 22;6(6):CD009092. [PMC free article: PMC9216234] [PubMed: 35731704]

45.Cicinelli E, Resta L, Nicoletti R, Zappimbulso V, Tartagni M, Saliani N. Endometrial micropolyps at fluid hysteroscopy suggest the existence of chronic endometritis. Hum Reprod. 2005 May;20(5):1386-9. [PubMed: 15734762]

46.Shoff SM, Newcomb PA. Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol. 1998 Aug 01;148(3):234-40. [PubMed: 9690359]

47.Nguyen PN, Nguyen VT. Assessment of paraclinical characteristics in peri- and postmenopausal bleeding women: is there a correlation between hemoglobin levels and ultrasonic indices? J Taibah Univ Med Sci. 2023 Jun;18(3):488-498. [PMC free article: PMC9906015] [PubMed: 36818167]

48.Practice Bulletin No. 141: Management of Menopausal Symptoms: Correction. Obstet Gynecol. 2018 Mar;131(3):604. [PubMed: 29470333]